108 results about "Acetyltransferase" patented technology

The invention belongs to the technical field of biology, and particularly relates to application of serine in relieving heat stress of pleurotus ostreatus and a method. Under the heat stress condition, exogenous serine supply promotes pleurotus ostreatus hypha to recover growth, and the activity of antioxidant enzyme, the yield of sporocarp and the yield of nutrient substances are improved; when the activity of the PHGDH enzyme is inhibited, the serine synthesis is reduced; the hypha growth can be promoted by overexpressing the phgdh, and the enzymatic activity of the PHGDH can be improved; when acetyltransferases HAT, NAT1, NAT2 and NAT3 act on a K394 site of the PHGDH, the enzyme activity of the PHGDH can be improved, endogenous serine metabolism is activated to respond to heat stress, it is indicated that PHGDH-mediated serine metabolism plays an important role in corresponding heat stress of the pleurotus ostreatus, and the invention discloses a mechanism for improving heat resistance of the pleurotus ostreatus through the PHGDH-mediated serine metabolism. And a foundation can be laid for breeding high-temperature-resistant pleurotus ostreatus dominant strains.

The invention discloses an aspergillus niger recombinant strain for degrading vomitoxin and application thereof, and belongs to the field of gene engineering. In order to solve the problem that a method for efficiently degrading vomitoxin is lacked in the prior art, the invention provides an aspergillus niger recombinant strain for degrading vomitoxin, the aspergillus niger strain for co-expressing FsTRI12 is taken as a recipient bacterium, a vomitoxin acetyltransferase gene segment is selected, an intracellular gene expression vector is constructed, and a homozygous aspergillus niger recombinant strain is screened. The aspergillus niger recombinant strain provided by the invention can be applied to degradation of vomitoxin, provides a new choice for effectively solving the vomitoxin pollution problem in cereal raw materials and feeds, reducing grain loss and guaranteeing food and feed safety, and has potential industrial application prospects.

The invention relates to construction and dyeing application of recombinant Escherichia coli for synthesizing indole acetate, which is characterized in that recombinant Escherichia coli MG1655 delta pheA delta trpR delta tyrA delta yddG delta arsB: tac 70-MaFMO delta ldhA: tac 70-MaFMO delta yghWX: tac 70-tnaA delta poxB: tac 70-cav1 is taken as an initial strain, then endogenous acetylesterase is knocked out, and the recombinant Escherichia coli for synthesizing indole acetate is obtained by the steps of: preparing the recombinant Escherichia coli for synthesizing indole acetate. An endogenous tryptophan hydrolase gene tnaA and a flavin-containing monooxygenase gene maFMO are overexpressed, and meanwhile, an acetyltransferase gene is overexpressed, so that the tryptophan-containing flavin-containing monooxygenase gene is obtained; the yield of the indole acetate reaches up to 195.3 mg / L. When the indole acetate is used for dyeing, a reducing agent and an enzyme solution are not used, so that the dyeing cost is greatly reduced.

Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.

The invention relates to a method of determining whether a patient diagnosed with inflammatory bowel disease (will respond to 5-ASA therapy which includes the steps of: obtaining a stool sample from the patient, analyzing the sample for the presence of microbial acetyltransferase genes capable of converting 5-ASA to the clinically ineffective N-acetyl 5-ASA, if microbial acetyltransferase genes are not present in the sample, the patient will respond to 5-ASA therapy and such therapy should be administered; if microbial acetyltransferase genes are present in the sample, the patient will not respond to 5-ASA therapy and a second line therapy should be administered.

The invention relates to the technical field of artificial design of enzymes, in particular to an artificial intelligence design and expression system construction method and system for lysosomal membrane protein type N-acetyltransferase with 11 transmembrane regions, and the method comprises the following steps: collecting reaction rate information of an enzyme and a substrate, associating a structure model with rate parameters, and comparing three-dimensional difference of residues, according to the method, by collecting the reaction rate correlation structure conformation, dynamic recognition of the key conformation state is achieved, the accuracy of three-dimensional space difference analysis is improved, host expression optimization factors are fused in the construction process, and the construction efficiency is improved. According to the method, the expression efficiency is improved, conformation function screening and structural stability parallel evaluation are carried out, the screening accuracy of efficient catalysis and stable expression is enhanced, three links of recognition, screening and construction are broken through, the target enzyme obtaining efficiency and expression quality are improved, and enzyme engineering is promoted to be developed towards high-throughput systematization.

The invention relates to the field of genetic engineering and fermentation engineering, and discloses a genetically engineered bacterium for producing melatonin and application of the genetically engineered bacterium in fermentation production of melatonin. According to the invention, genes of mtrA, PTPS, SPR, PCD and DHPR of related enzymes synthesized by coding 2-amino-6-(1, 2-dihydroxypropyl)-5, 6, 7, 8-tetrahydro-4 (1H)-pterin diketone and genes of L-2-amino-3 (beta-indole) propionic acid monooxygenase, oxymethyltransferase, N-acetyltransferase and decarboxylase are co-expressed on the genetically engineered bacterium, so that the gene engineering bacterium is obtained. The strain can be used for fermentation production of melatonin, and experiments show that the yield of the strain can reach 6480 mg / L.

The invention discloses genetically engineered corynebacterium glutamicum and an application of the genetically engineered corynebacterium glutamicum in preparation of ectoine, and the genetically engineered corynebacterium glutamicum contains an L-diaminobutyric acid transaminase gene ectB, an L-diaminobutyric acid acetyltransferase gene ectA and an ectoine synthetase gene ectC, the invention relates to an aspartic acid transferase gene aspB, an aspartic acid kinase gene lysC and an aspartic acid semialdehyde dehydrogenase gene asd, wherein the nucleotide sequences of the gene aspB, the gene lysC and the gene asd are respectively as shown in SEQ ID NO.4, SEQ ID NO.5 and SEQ ID NO.6. The invention further discloses a preparation method of the aspartic acid transferase gene aspB, the aspartic acid kinase gene lysC and the aspartic acid semialdehyde dehydrogenase gene asd. After the recombinant corynebacterium glutamicum constructed by the invention is fermented for 60 hours, the yield of ectoine can reach 50g / L. The genetically engineered corynebacterium glutamicum disclosed by the invention has important practical significance on industrial production and large-scale application of ectoine.

The invention belongs to the technical field of biological medicine, and particularly relates to a biomarker related to acetylation of a K147 site of histone H1 and application of the biomarker in liver cancer treatment. The invention relates to a biomarker related to acetylation of a K147 site of histone H1. According to the biomarker, the histone H1 is subjected to acetylation modification at the K147 site. Bioinformatics analysis shows that the high expression state of acetyltransferase ELP3 is closely related to the occurrence and development of hepatocellular carcinoma, ELP3 can directly regulate and control acetylation modification of histone H1, then the core catalytic site of ELP3 is verified through site mutation, and the K147 acetylation site located on the histone H1 is precisely determined. Test results show that intervention of the ELP3-H1-K147 pathway can significantly inhibit proliferation and migration ability of liver cancer cells, and can provide research and development direction and theoretical support for development of novel liver cancer treatment drugs.

The present invention relates to a method for producing triterpenoids using one or more of the following polypeptides: (i) Saponaria officinalis synthase (SobAS), (ii) S. officinalis C28 oxidase (SoC28), (iii) S. officinalis C28C16 oxidase (SoC28C16), (iv) S. officinalis C23 oxidase (SoC23), (v) S. officinalis QA 3-O-glucuronosyltransferase (“SoCSL”), (vi) S. officinalis QA-GlcA galactosyltransferase (“SoC3Gal”), (vii) S. officinalis QA-GlcA-Gal xylosyltransferase (“SoC3Xyl”), (viii) S. officinalis QA-Tri fucosyltransferase (“SoC28Fu”), (ix) S. officinalis QA-TriF rhamnosyltransferase (“SoC28Rha”), (x) S. officinalis QA-TriFR xylosyltransferase (“SoC28Xyl1”), (xi) S. officinalis QA-TriFRX xylosyltransferase (“SoC28Xyl2”), (xii) S. officinalis QA-TriFRXX quinovosyltransferase (“SoGH1”), and (xiii) S. officinalis QA-TriF(Q)RXX acetyltransferase (“SoBAHD1”). Methods, host cells, isolated polypeptides, nucleic acids, and plants are provided.

The present invention relates to an antisense oligonucleotide (oligomer) complementary to NAT8L (N-acetyltransferase 8-like) precursor mRNA, which is capable of inhibiting the expression of NAT8L in a cell that expresses NAT8L. Inhibition of the expression of NAT8L is beneficial to the treatment of Canadian disease (Canadian disease).

Certain embodiments of the invention pertain to a method of treating an infection in a subject caused by an infectious agent other than Escherichia coli, the method comprising administering to the subject arsinothricin or a salt thereof. The infectious agent other than E. coli can be a bacterium, protozoan, helminth, archaebacterium, or a fungus. In preferred embodiments, the infectious agent is Mycobacterium tuberculosis, Mycobacterium bovis, or Enterobacter cloacae. The invention also pertains to a method of treating an infection in a subject caused by an infectious agent, comprising administering to the subject arsinothricin or a salt thereof in combination with an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. In certain such embodiments, the infectious agent expresses phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase. Further embodiments provide compositions comprising arsinothricin or a salt thereof and an inhibitor of phosphinothricin N-acetyltransferase or arsinothricin N-acetyltransferase.

This invention provides an engineered bacterium for producing ectoine, its preparation method, and its application. The engineered bacterium is prepared using a method comprising the following steps: using *Corynebacterium glutamicum* as the starting strain, feedback inhibition by aspartate kinase LysC is relieved, the activity of the gene lysE encoding lysine efflux permease is reduced, and the ectoine synthesis gene cluster ectABC is expressed. Based on this, the activity of any one or at least two of the following—diaminobutyrate acetyltransferase EctA, pyruvate carboxylase Pyc, or aspartate kinase LysC—is enhanced, and / or the activity of any one or at least two of the following—maloquinone oxidoreductase Mqo or homoserine dehydrogenase Hom—is reduced to further increase ectoine yield.

The invention belongs to the technical field of medicines, and generally relates to application of N-acetyl-L-tyrosine and an N-acetyltransferase strain for expressing tyrosine in preparation of tumor treatment drugs or anti-tumor immune activation drugs for elderly individuals. Researches find that N-acetyl-L-tyrosine and a tyrosine-expressing N-acetyltransferase strain can significantly inhibit mouse tumors, which shows that the mouse tumors grow slowly or the number of the mouse tumors is reduced. The N-acetyl-L-tyrosine can also regulate anti-tumor immunity, and is expressed as promoting TCF1 expression and increasing the proportion of depleted precursor T cells. In the elderly, the curative effect is particularly prominent. The results show that N-acetyl-L-tyrosine and related strains thereof can be used for tumor treatment and anti-tumor immune aging regulation.

The invention provides an engineering bacterium for producing spermidine and a preparation method of the engineering bacterium, and relates to the field of genetic engineering. According to the invention, arginine decarboxylase, aspartate kinase, aspartate-semialdehyde dehydrogenase, spermidine efflux protein (MdtI / MdtJ), carboxylaminopropyl agmatine dehydrogenase (CAPADH), carboxylaminopropyl agmatine decarboxylase (CAPADC) and aminopropyl agmatine urea hydrolase (APAUH) are subjected to overexpression in escherichia coli by using a gene engineering technology, and then the escherichia coli is subjected to enzyme deactivation, so that the escherichia coli is obtained. The genetically engineered bacterium capable of producing the spermidine can be obtained by simultaneously knocking out a spermidine transport system (PotBCAD), a spermidine-N-acetyltransferase (spermidine-N-acetyltransferase) and a homoserine dehydrogenase (homoserine dehydrogenase), so that the genetically engineered bacterium capable of producing the spermidine can be obtained. The engineering bacterium greatly reduces the production cost of spermidine, has a wide application prospect, and lays a foundation for green production of spermidine.

A genetically engineered strain of Escherichia coli Nissle 1917 (EcN) with a modified genome designed to enhance the production of short-chain fatty acids (SCFAs) is provided. The engineered genome includes the atoB gene from E. coli K-12, responsible for encoding acetyl-CoA acetyltransferase, a crt-bcd-etfA-etfB-BHBD gene cluster from E. C. butyricum that encodes enzymes involved in the synthesis of SCFAs, specifically enoyl-CoA hydratase, butyryl-CoA dehydrogenase, and electron transfer flavoproteins, and the ptb-buk gene from C. acetobutyricum, which encodes phosphotransbutyrylase and butyrate kinase. Additionally, key genes associated with competing metabolic pathways—ldhA, frdABCD, adhE, ackA, and pta—are deleted to optimize SCFA production, particularly butyrate. This strain is intended for use in therapeutic applications where enhanced SCFA production is beneficial, such as in the treatment of coronary heart disease.

The present invention relates to the use of a known enzyme ‘denominated as a Starmerella bombicola lactone esterase (Sble)’ to perform a transesterification and / or hydrolysis reaction. More specifically the Sble enzyme performs a transesterification and / or hydrolysis reaction on bola amphiphilic glycolipids. The invention indeed discloses that said Sble is capable to convert bola sophorolipids into lactonic and / or acidic sophorolipids and saccharides, and, that yeast strains containing a non-functional or dysfunctional Sble enzyme and / or a disabled sble gene and / or not containing the sble gene produce (acetylated) bola amphiphilic glycolipids. In addition, the invention further discloses a method to produce non-acetylated (bola) amphiphilic glycolipids via rendering acetyltransferase enzymes At1, At2 and At3 non-functional or dysfunctional in the latter yeast strains and / or by modifying strains so that they do not contain the acetyltransferase αt1, αt2 and αt3 gene(s) and / or by strains not containing the αt1, αt2 and αt3 gene(s). Moreover, upon rendering the glucosyltransferase B (UgtB1) non-functional or dysfunctional in the abovementioned strains and / or upon removing and / or disabling the ugtB1 gene and / or by strains not containing the ugtB1 gene these produce acetylated and / or non-acetylated bola amphiphilic glucolipids. The invention further discloses a method to produce non-acetylated glycolipids via rendering acetyltransferase enzymes At1, At2 and / or At3 non-functional or dysfunctional and / or removing and / or disabling the glycolipid acetyltransferase genes in glycolipid producing yeast strains and / or by strains not containing the αt1, αt2 and αt3 gene(s).

The invention relates to a group of taxane compounds as well as a preparation method and application thereof. Specifically, the invention provides application of enzymes with hydroxylase, epoxidation, acylase and / or oxetane synthase activity as shown in SEQ ID NO.2, 4, 6 and 8 in catalyzing hydroxylation, epoxidation, acylation and / or oxetane alkylation of taxane compounds. The P450 and / or acetyltransferase can perform hydroxylation on C9, C1 and C7 sites of taxane compounds, so that the taxane compounds can be converted into taxane compounds, and the taxane compounds can be converted into taxane compounds, so that the taxane compounds can be converted into taxane compounds, the taxane compounds can be converted into taxane compounds, and the taxane compounds can be converted into taxane compounds, and the taxane compounds can be converted into taxane compounds. The C4 and C20 of the taxane compound can be subjected to epoxidation liquid separation, the C4, C5 and C20 can be subjected to oxetanylation, and the C7 position of the taxane compound can also be subjected to acylation.

The present application relates to the technical field of genetic engineering, and discloses a recombinant Escherichia coli for high-yield O-acetyl-L-homoserine and application thereof. The recombinant Escherichia coli for high-yield O-acetyl-L-homoserine is obtained by the following combination of modification strategies: in Escherichia coli W3110, a gene encoding homoserine O-acetyltransferase is integrated into a gene site encoding L-arginine ABC transporter ATP binding subunit, then a gene encoding phosphoacetyltransferase is knocked out, then a gene encoding transcriptional anti-terminator and mRNA stability regulator is knocked out, then a gene encoding ATP-NAD kinase is integrated into a gene site encoding NADPH-dependent aldehyde reductase, and finally a gene promoter of acetyl-CoA synthetase is replaced by a Ptrc promoter to obtain the recombinant Escherichia coli. The recombinant Escherichia coli is used for fermentation to produce O-acetyl-L-homoserine, and has the advantage of high yield. metx artp patz cspc ppnk yahk acs ​​​​​​​

The invention relates to a method for heterologously producing ganoderic acid, which comprises the following steps: respectively transforming candidate oxidase, candidate reductase and candidate acetyltransferase into corresponding saccharomyces cerevisiae strains for heterologously expressing, and screening the transformed strains through intracellular fermentation or whole-cell catalysis to obtain codon-optimized AfuSDR and CsSDR capable of catalyzing oxidization of hydroxyl of a ganoderma triterpene skeleton C3, the method comprises the following steps of: performing independent expression or combined expression on reductases AKR1C2, AKR1C4 and FusC1 which are optimized by codons and are used for catalyzing C3 keto reduction and acetyltransferase BsAT which is optimized by codons and is used for catalyzing C3 hydroxyl acetylation, so as to realize heterologous biosynthesis of ganoderic acid TR (GA-TR), gibberellic acid Ja (GA-Ja) and ganoderic acid Mf (GA-Mf).

This invention relates to the construction and staining application of recombinant Escherichia coli for synthesizing indoleacetic acid ester. The recombinant Escherichia coli for synthesizing indoleacetic acid ester is obtained by using recombinant Escherichia coli MG1655ΔpheAΔtrpRΔtyrAΔyddGΔarsB::tac70-MaFMOΔldhA::tac70-MaFMOΔyghWX::tac70-tnaAΔpoxB::tac70-cav1 as the initial strain. Then, the endogenous acetylesterase is knocked out, and the endogenous tryptophan hydrolase gene tnaA and the flavin monooxygenase gene maFMO are overexpressed, while simultaneously overexpressing the acetyltransferase gene. The indoleacetic acid ester yield of this invention is as high as 195.3 mg / L. Using indoleacetic acid ester for staining eliminates the need for reducing agents and enzyme solutions, significantly reducing staining costs.

The invention discloses a method for efficiently detecting various microbial limits of tobramycin, belongs to the technical field of microbial detection, and initiates an enzyme-chemical synergistic neutralization system constructed by aminoglycoside-3-acetyltransferase, aminoglycoside-3 '-phosphotransferase, magnesium chloride hexahydrate and a sodium chloride-peptone buffer solution. According to the system, the bacteriostatic activity of tobramycin can be thoroughly eliminated through a direct enzymatic inactivation way, and the limitation that neutralization is not thorough in a traditional method is broken through. Based on the system, the efficient detection method is successfully developed by combining process optimization of adding bacteria and adding a passivating enzyme and a chemical neutralizer into a culture medium. The method has four core advantages of high efficiency, specificity, environmental protection and synergy, can thoroughly eliminate antibacterial interference of tobramycin, and remarkably improves the accuracy and reliability of a microbial limit test result.

The present invention relates to a method of selecting a subject having cancer for treatment comprising: i) determining a KAT6A level of a biological sample of cancer from said subject; ii) selecting a subject for treatment; and iii) administering to the selected subject an amount of one of the following based on the KAT6A level: a) a lysine acetyltransferase 6A (KAT6A) inhibitor; b) a lysine acetyltransferase 6A (KAT6A) inhibitor and a cyclin dependent kinase 4 (CDK4) inhibitor; c) a lysine acetyltransferase 6A (KAT6A) inhibitor and an antiestrogen; and d) a lysine acetyltransferase 6A (KAT6A) inhibitor, a cyclin dependent kinase 4 (CDK4) inhibitor, and an antiestrogen, wherein the KAT6A level is determined as a high KAT6A level.

This invention discloses a genetically engineered bacterium lacking the acetyltransferase gene asp12, its construction method, and its applications. This invention utilizes CRISPR / Cas9 to knock out the asp12 gene encoding acetyltransferase in Aspergillus terreus strain GZU-31-1, constructing the genetically engineered bacterium Δasp12. This invention found that compared to the wild-type Aspergillus terreus strain GZU-31-1, the genetically engineered bacterium Δasp12 exhibits increased accumulation and significantly higher yield of the compound Aspermeroterpene F, which possesses anti-inflammatory and anti-hepatic fibrosis activities. Based on the genetically engineered bacterium Δasp12, this invention also provides a method for preparing the compound Aspermeroterpene F, further improving the yield of the compound by optimizing the fermentation culture medium. This invention is beneficial for the development of anti-inflammatory and anti-hepatic fibrosis drugs.

The invention relates to the field of synthesis of natural dyes by genetic engineering and a biological method, in particular to a recombinant engineering bacterium for synthesizing N-acetyl blue as well as a construction method and application of the recombinant engineering bacterium. According to the invention, Escherichia coli BL21 (DE3) is used as an initial strain for modification; the method comprises the following steps: by using a genetic engineering bacterium as a template, expressing an ornamental blue synthetase encoding gene bpsA, a 4 '-phosphoric acid pantetheinyl transferase encoding gene entD, a glutamine synthetase encoding gene glnA, a glutamate dehydrogenase encoding gene gdhA, an acetyl-coenzyme A synthetase encoding gene acs and N-acetyltransferase encoding genes from different sources, and constructing to obtain a recombinant engineering bacterium. The recombinant engineering bacteria take sodium acetate as a substrate, and the sodium acetate not only meets the growth requirements of cells, but also can provide sufficient precursor substances. After the recombinant engineering bacterium constructed by the invention is subjected to shake flask fermentation culture for 72 hours, the purity of the N-acetyl blue can be up to 99% or above, and the recombinant engineering bacterium has the potential of industrial application.

The invention relates to the technical field of microorganisms, in particular to lactobacillus brevis X4-4 and application of the lactobacillus brevis X4-4 in fermentation. The preservation number of the lactobacillus brevis X4-4 provided by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 31284. The activity of pyruvate dehydrogenase, malic acid-lactase, N-acetyltransferase and acid protease of the strain is remarkably higher than that of existing common lactobacillus, malic acid and protein in food raw materials can be efficiently utilized, and beneficial products can be generated. The lactobacillus brevis X4-4 has the specific advantages that 1) the lactobacillus brevis X4-4 can survive in a large quantity in an environment with relatively low pH (Potential of Hydrogen); (2) malic acid is converted into lactic acid which participates in pyruvic acid metabolism and arginine synthesis, so that the irritative sour feeling of the raw materials is reduced; (3) protein can be hydrolyzed into small molecule peptide under an acidic condition, so that the utilization rate of the protein is increased; and 4) the method can be used for single fruit raw materials or high-protein raw materials, and can also be used for fruit and protein composite raw materials.

The invention relates to an Escherichia coli engineering strain for producing 2, 3-hexanediol as well as a construction method and application of the Escherichia coli engineering strain, and the method comprises the following steps: constructing recombinant plasmids pET-FadB-Ter-PhaA for expressing FadB genes of 3-hydroxyacetyl-CoA dehydrogenase and enoyl-CoA hydratase, Ter genes of trans-enoyl-CoA reductase and PhaA genes of acetyl-CoA acetyltransferase; the method comprises the following steps: constructing a recombinant plasmid pRSF-Ilv2C-PduP for expressing an Ilv2C gene of acetohydroxy acid synthetase and a PduP gene of CoA-acylated aldehyde dehydrogenase; and chemically converting the recombinant plasmid pET-FadB-Ter-PhaA and the recombinant plasmid pRSF-Ilv2C-PduP into escherichia coli, so as to obtain the escherichia coli engineering strain for producing the 2, 3-hexanediol. The Escherichia coli engineering strain realizes microbial de novo synthesis of linear beta, gamma-hexanediol for the first time, fills the vacancy in the field of biosynthesis of dihydric alcohol, and expands the application prospect of dihydric alcohol.

The present invention relates to a microorganism containing at least one heterologous gene encoding L-arginine:glycine amidinotransferase (AGAT), at least one heterologous L-threonine 3-dehydrogenase gene (tdh), and at least one heterologous glycine C-acetyltransferase (2-amino-3-oxobutanoate coenzyme A ligase) gene (kbl), as well as a method for the fermentative production of guanidinoacetic acid (GAA) using such a microorganism. The present invention also relates to a method for the fermentative production of creatine.

The invention provides an arylalkylamine N-acetyltransferase mutant and an application of the arylalkylamine N-acetyltransferase mutant in synthesis of N-acetyl-5-hydroxytryptamine. According to the invention, a series of mutants with N-acetylation activity are obtained through gene mining, directed evolution and the like, and the mutants can directly acetylate a substrate 5-hydroxytryptamine to generate N-acetyl-5-hydroxytryptamine. Therefore, the arylalkylamine N-acetyltransferase mutants have important application value in the industry.